Amneal Pharmaceuticals Inc. (AMRX) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Amneal Pharmaceuticals In... (AMRX)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

7.86

0.14 (1.81%)

At close: Jan 14, 2025, 3:59 PM

7.85

-0.13%

After-hours Jan 14, 2025, 04:38 PM EST

undefined% (undefined)

Bid	6.58
Market Cap	3.75B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.83
PE Ratio (ttm)	-9.47
Forward PE	n/a
Analyst	Buy

Ask	8.8
Volume	636,983
Avg. Volume (20D)	1,078,896
Open	7.73
Previous Close	7.72
Day's Range	7.69 - 7.88
52-Week Range	5.01 - 9.47
Beta	undefined

About AMRX

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation produc...

[Show more]

Industry Drug Manufacturers - Specialty & Generic

Sector Healthcare

IPO Date May 7, 2018

Employees 7,850

Stock Exchange NYSE

Ticker Symbol AMRX

Website https://www.amneal.com

Analyst Forecast

According to 5 analyst ratings, the average rating for AMRX stock is "Buy." The 12-month stock price forecast is $10, which is an increase of 27.23% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Amneal Pharmaceuticals Inc. is scheduled to release its earnings on Feb 28, 2025, before market opens.
Analysts project revenue of $700.83M, reflecting a 13.59% YoY growth and earnings per share of 0.15, making a 7.14% increase YoY.

Why Price Moved

2 months ago · Source

+5.38%

Amneal Pharmaceuticals shares are trading higher a... Unlock content with Pro Subscription

2 months ago · Source

-1.28%

Amneal Pharmaceuticals shares are trading higher after the company announced FDA approval of its New Drug Application for Pyridostigmine Bromide Extended-Release Tablets.

News

6 days ago · zacks.com

Amneal (AMRX) Upgraded to Strong Buy: Here's Why

Amneal (AMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 month ago · businesswire.com

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist.

2 months ago · zacks.com

AMNEAL PHARMACEUTICALS, INC. (AMRX) Hit a 52 Week High, Can the Run Continue?

Amneal (AMRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

2 months ago · seekingalpha.com

Amneal Pharmaceuticals, Inc. (AMRX) Q3 2024 Earnings Call Transcript

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX ) Q3 2024 Earnings Conference Call November 8, 2024 8:30 AM ET Company Participants Tony DiMeo - Head of Investor Relations Chirag Patel - President & Co-Chie...

2 months ago · zacks.com

Amneal (AMRX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

While the top- and bottom-line numbers for Amneal (AMRX) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compar...

2 months ago · zacks.com

Amneal Pharmaceuticals (AMRX) Surpasses Q3 Earnings and Revenue Estimates

Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.19 per share a year ago.

2 months ago · businesswire.com

Amneal Reports Third Quarter 2024 Financial Results

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Amneal Reports Third Quarter 2024 Financial Results.

2 months ago · zacks.com

Amneal (AMRX) Q3 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Evaluate the expected performance of Amneal (AMRX) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics...

2 months ago · zacks.com

5 Stocks Backed by High Efficiency for Solid Gains Amid Volatility

Invest in stocks of AMRX, CRON, CSV, BFST and APH to tap their high-efficiency levels.

2 months ago · zacks.com

Earnings Preview: Amneal Pharmaceuticals (AMRX) Q3 Earnings Expected to Decline

Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago · zacks.com

How to Find Great Cheap Stocks Under $10 to Buy in October

On top of their cheap price tags, Wall Street analysts are high on all of these stocks and their improving earnings outlooks earn them strong Zacks Ranks.